Which has the lower trailing P/E, ILMN or TEVA?

ILMN has the lower trailing P/E: ILMN trades at 50.94 and TEVA at 65.88. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, ILMN or TEVA?

Over the past five years, ILMN grew revenue faster — ILMN at a 5.04% CAGR versus TEVA at 1.19%.

Is ILMN or TEVA more profitable?

ILMN runs the higher net margin — ILMN at 18.36% versus TEVA at 4.08%.

How have ILMN and TEVA total returns compared?

Over the past 10 years, ILMN delivered 4.17% and TEVA delivered -1.15% annualized total return. Past performance doesn't predict future results.

Illumina, Inc. (ILMN) vs Teva Pharmaceutical Industries Limited (TEVA)

A side-by-side comparison of Illumina, Inc. and Teva Pharmaceutical Industries Limited across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 2, 2026. Differences are shown without an overall score or investment verdict.

ILMN

Illumina, Inc.

$41.31B

$273.04HealthcareDelayed quote: Oct 2, 2026, 4:00 PM EDT

TEVA

Teva Pharmaceutical Industries Limited

$46.04B

$39.53HealthcareDelayed quote: Oct 2, 2026, 4:00 PM EDT

Total return — ILMN vs TEVA

growth of $100 · dividends reinvested · last 10y

ILMN +48.2% (+4.0%/yr)TEVA -15.8% (-1.7%/yr)ILMN compounded faster over this window

ILMN TEVA

ILMN vs TEVA: by the numbers

•TEVA is the larger company ($46.04B vs $41.31B market cap).
•ILMN trades at the lower trailing earnings multiple (50.94 vs 65.88 P/E), one valuation lens rather than an overall verdict.
•ILMN converts more revenue to profit (18.36% vs 4.08% net margin).
•ILMN grew revenue faster over the past five years (5.04% vs 1.19% CAGR).

Metrics side by side

Valuation

Metric	ILMN	TEVA
P/E ratio	50.94	65.88
Forward P/E	51.00	20.04
PEG ratio	11.99	N/A
P/S ratio	9.19	2.66
P/B ratio	14.56	5.94
EV / EBITDA	35.22	19.94
FCF yield	2.27%	2.93%

Profitability

Metric	ILMN	TEVA
Gross margin	66.79%	52.47%
Operating margin	20.97%	11.45%
Net margin	18.36%	4.08%
ROE	29.07%	9.10%
ROIC	13.74%	6.79%

Growth (annualized)

Metric	ILMN	TEVA
Revenue CAGR (5Y)	5.04%	1.19%
EPS CAGR (5Y)	4.22%	N/A
FCF CAGR (5Y)	1.03%	N/A
Total return CAGR (5Y)	-7.09%	32.30%

Frequently asked

Which has the lower trailing P/E, ILMN or TEVA?: ILMN has the lower trailing P/E: ILMN trades at 50.94 and TEVA at 65.88. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, ILMN or TEVA?: Over the past five years, ILMN grew revenue faster — ILMN at a 5.04% CAGR versus TEVA at 1.19%.
Is ILMN or TEVA more profitable?: ILMN runs the higher net margin — ILMN at 18.36% versus TEVA at 4.08%.
How have ILMN and TEVA total returns compared?: Over the past 10 years, ILMN delivered 4.17% and TEVA delivered -1.15% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ILMN analysis Full TEVA analysis Interactive comparison tool

Dig into the metrics

Illumina P/E ratio Teva Pharmaceutical Industries P/E ratio Illumina ROE Teva Pharmaceutical Industries ROE Illumina operating margin Teva Pharmaceutical Industries operating margin Illumina revenue growth Teva Pharmaceutical Industries revenue growth Illumina free cash flow Teva Pharmaceutical Industries free cash flow

Illumina & Teva Pharmaceutical Industries appear in these rankings

Highest ROE Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 2, 2026.